The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.

Login to TechFinder » 

PRKCi, atypical protein kinase C, inhibitors for hedgehog dependent cancers


Stanford Reference:

11-151


Abstract


The Hedgehog pathway is abnormally active in a wide variety of human cancers including basal cell carcinomas (BCCs), and medulloblastomas. First generation pathway inhibitors target the G protein coupled receptor Smo, but tumors can develop activating Smo mutations that confer resistance. Stanford researchers have identified atypical protein kinase C iota type (PRKCi) as a positive regulator of the pathway in BCCs and medulloblastomas. The researchers found that the kinase acts downstream of Smo, indicating it may be useful in Smo inhibitor-resistant tumors. Using a mouse model the researchers find that PSI, a pseudosubtrate inhibitor of PRKCi, dramatically reduces Hedgehog pathway activity in BCCs while reducing tumor growth.

Continuing Research
The researchers are working on optimizing the selection and design of the PRKCi inhibitor. They plan to explore its effect with other cancers in which the Hedgehog pathway is implicated.

Applications


  • Treatment of hedgehog dependent tumors, particularly those that are resistant to Smo inhibitors.

Advantages


  • The current state of the art is to treat patients with Smo inhibitors. Because PRKCi and its inhibitors act downstream of Smo, this can be effective therapy for patients who gain resistance to Smo inhibitors.

Publications



Related Web Links



Innovators & Portfolio



Patent Status



Date Released

 7/24/2013
 

Licensing Contact


Gregg Kyle, Senior Licensing Associate
+1-650-725-3476 (Direct)
Login to Request Information

[-] Map/Timeline

00-252 Isozyme-selective PKC Inhibitors and Activators
02-103 γPKC and εPKC Inhibitors for Treatment of Pain
03-078 Peptides for Highly Efficient Cancer Immunotherapy

more technologies

Related Keywords


basal cell carcinoma   smo inhibitor   Smo receptor inhibitors   aPKC inhibitor   anti-tumor   tumor targeting   therapeutic: cell signalling   
 

   

  

Also of Interest...
00-252 Isozyme-selective PKC Inhibitors and Activators
02-103 γPKC and εPKC Inhibitors for Treatment of Pain
03-078 Peptides for Highly Efficient Cancer Immunotherapy

Recently Viewed...
S11-151 PRKCi